Xilio Therapeutics (XLO) Announces Pipeline Updates, Reports Q3 Reults
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 5/26/2022
- Wall Street jumps on upbeat retail guidance, easing Fed fears
- Broadcom (AVGO) to Acquire VMware (VMW) for Approximately $61 Billion in Cash and Stock
- NVIDIA (NVDA) Falls on Downbeat Guidance, Evercore ISI Remains a Buyer as Shares Trade Near an 'Estimated Floor of $150'
- Apple (AAPL) Stock Dips on Report It Expects Flat iPhone Production This Year
- Macy's (M) Stock Up 15% on Beat-and-raise, Goldman Sachs Says Results are a 'Bright Spot Among Retailers'
- Wells Fargo (WFC) has fired dozens of loan officers accused of misusing appraisal waivers. Some say the bank gave them mixed signals - Business Insider
- Apple (AAPL) Reportedly Behind Schedule in Development of the New iPhone, Analyst Cuts Price Target on Risk to June Quarter iPhone Revenue
- Broadcom (AVGO) to Acquire VMware (VMW) for Approximately $61 Billion in Cash and Stock
- Wall Street rallies as Fed minutes meet expectations
- Michael Burry Posts Cryptic Tweet Raising Spector of 2008 Crash - Bloomberg
- Pre-Open Stock Movers 05/26: Retailers Dollar Tree, Macy's, and Williams-Sonoma Jump on Results; Nutanix, Snowflake, NVIDIA Fall (more...)
- After-Hours Stock Movers 05/25: NVIDIA, Snowflake Sink on Weaker Guidance; Williams-Sonoma Surges on Strong Numbers (more...)
- Pre-Open Stock Movers 05/25: Retailers Express, Nordstrom Gain Following Earnings; Verrica Pharma Sinks on FDA CRL (more...)
- Companies with NDRs 5/25
- After-Hours Stock Movers 05/24: Wendy's Gains on Possible Peltz Deal, Nordstrom Up Following Earnings (more...)
Xilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results
December 2, 2021 7:30 AM ESTAnticipate First Patient Dosing in Phase 1/2 Clinical Trial for XTX202, a Tumor-Selective IL-2, in First Quarter of 2022
Advancing Phase 1/2 Clinical Trial for XTX101, a Tumor-Selective Anti-CTLA-4
Successfully Closed IPO in Fourth Quarter of 2021, Raising Approximately $130 Million in Gross Proceeds to Advance Pipeline of Tumor-Selective Immuno-Oncology Programs
WALTHAM, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, today reported recent pipeline and business progress and third quarter 2021 financial results.
Xilio made significant... More
